8000 Marina Boulevard
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients.
135 articles with Aimmune Therapeutics
Pre-Market Research Reports on Biotech Stocks -- Agenus, Aimmune Therapeutics, Akebia Therapeutics, and Alder Biopharma
On Tuesday, key US indices were mixed as the NASDAQ Composite finished the trading session down 0.01%; the Dow Jones Industrial Average edged 0.79% higher; and the S&P 500 was up 0.48%.
Aimmune Therapeutics, Inc. today announced the appointment of Jayson Dallas, M.D., as President and Chief Executive Officer.
Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
Aimmune Therapeutics, Inc. announced that data from a new study on the psychosocial burden of peanut allergy in European countries were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich.
Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018
Aimmune Therapeutics, Inc. announced that data on terminology used with oral immunotherapy were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich.
Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy
Company began 2018 with approximately $182 Million in cash and investments
Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
immune Therapeutics, Inc. announced that the results of its pivotal Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy were presented today at the 2018 American Academy of Allergy, Asthma & Immunology–World Allergy Organization Joint Congress in Orlando.
Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
Underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share have exercised in full their option to purchase an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock
Aimmune Therapeutics announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of its common stock.
Aimmune Therapeutics announced late-stage trial results that showed its peanut allergy therapy was effective in more than 67 percent of juvenile patients.
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
Aimmune today announced the expansion of its Scientific Advisory Board with the appointments of George du Toit, M.B., B.Ch., a Professor of Paediatric Allergy at King’s College London, Guy’s and St. Thomas’ NHS Foundation Trust, and Wayne G. Shreffler, M.D., Ph.D., Chief of Pediatric Allergy and Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and Associate Professor of Pediatrics at Harvard Medical School.
Aimmune Therapeutics today announced that it will present data during a late-breaking oral abstract session and in poster sessions at the 2018 American Academy of Allergy, Asthma & Immunology–World Allergy Organization Joint Congress, taking place March 2–5 in Orlando.
Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
Aimmune today announced an expansion and extension of its exclusive supply agreement with Golden Peanut and Tree Nuts (Golden), a subsidiary of Archer Daniels Midland Company (ADM), to support the anticipated potential commercialization of AR101.
Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase III PALISADE Trial of AR101 for Peanut Allergy
Following expected topline results in February, Aimmune will report more detailed data from the PALISADE trial in a late-breaking oral abstract presentation on Sunday, March 4, 2018, at the American Academy of Allergy, Asthma & Immunology–World Allergy Organization Joint Congress in Orlando.
Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment With Leading Expert Allergists on Friday, December 1
The event will bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy.
Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase II Clinical Trial
The ARC001 study met its primary endpoint, providing evidence that AR101 has immunomodulatory activity, which, after approximately six months of treatment, significantly reduced clinical reactivity in almost 80 percent of the peanut-allergic subjects randomized to AR101 treatment.
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
Aimmune Therapeutics, Inc., today announced a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi to study AR101 treatment with adjunctive dupilumab in peanut-allergic patients in a Phase 2 clinical trial.
Aimmune’ Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy